• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • Composition of Methods (COM)
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Grok 4 aids Exit
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Evelina Cohn Budu, PhD – Inventor of Biologics, Small Molecules and Diagnostics

Evelina Cohn Budu, PhD – Inventor of Biologics, Small Molecules and Diagnostics

Roles at GDE: LPBI & M3DP:

EAW Status changed to Inactive on 2/19/2016

 

  • Expert, Author, Writer
  1. Alzheimer’s Disease
  2. Biomarkers & Medical Diagnostics
  3. BioSimilars
  4. Cell Biology, Signaling & Cell Circuits
  5. Cerebro-vascular and Neurodegenerative Diseases
  6. Chemical Biology and its relations to Metabolic Disease
  7. Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics
  8. Infectious Disease & New Antibiotic Targets
  9. Nanotechnology for Drug Delivery
  10. Proteomics
  11. Scientist: Career considerations
  12. Systemic Inflammatory Response Related Disorders
  13. Technology Transfer: Biotech and Pharmaceutical
  • Inventor of Biologics, Small Molecules and Diagnostics
  • Intellectual Property Developer in Medical 3D BioPrinting in the R&D Department of M3DP

BIO

Executive Director and Founder

EVCO Scientific Inc. is a start-up non-profit laboratory based in Pennsylvania dedicated to research the causes of Multiple sclerosis and other degenerative disorders. Its founder and Executive Director, Dr. Evelina Cohn has conducted influential research into Biochemistry, Cell Biology and Microbiology in Romania, Israel, USA and Canada, specializing in Lectinology and Pharmacology.

Dr Cohn is a research scientist with experience and contributions in Biochemistry, Cell Biology and Microbiology, with major accomplishments in biochemical separation and novel glycoproteins in serum modulation and their role in diagnostic of a certain diseases; as well as, methods for determination of apoptosis in cancer cells, by using new penetrable peptides. Dr. Cohn is a new type of idea leader in medical research, trying to combine her valuable expertise with new approaches in neurodegenerative field. She finished her Ph.D. in Life Sciences at Bar Ilan University, Ramat Gan Israel and Received B.S. in Biochemistry from University of Bucharest, Bucharest, Romania. Dr Cohn is co-inventor of a patent and inventor of a provisional patent on apoptosis methods using penetrable peptides and new methods of separation of novel glycoproteins in serum respectively. Dr. Cohn was the CEO of TelBari Inc, a Therapeutic Skin Care Company, where she developed her managing and marketing skills. She has successfully resolved two open innovation chemistry challenges with Idea Connection (www.ideaconnection.com). Current activities include a new point of care testing for traumatic brain injury as well as diagnostic laboratory procedures for neurodegenerative diseases. She was recently appointed as an Innovation Consultant for Idea Connection proudly representing Idea Connection philosophy in different parts of the world.

She isolated for the first time a lectin from Fir (Christmas tree), which showed anti- tumor activities towards colon cancer cell line, research presented in 2002 at the International Conference in Lectinology INTERLEC, in Copenhagen.

She is co-author of a patent regarding” Composition and method for increasing apoptosis in cancer cells” Patent # 7,408,022 , accredited in 2008 and author of a US provisional patent regarding “Novel Polymorphic Protective Glycoproteins and Methods “ Appl #61920414.

PATENTS

2008-Patent

“Composition and method for increasing apoptosis in cancer cells”-Patent #7,408,022  Inventors: Yao-Zhong Lin and Claudia E. Budu

http://www.patentstorm.us/patents/7408022/description.html 

PUBLICATIONS                   

2011- Articles in Scientific Journals with a National Referee System

Budu C.E., Ianculescu M Fir Bark (Abies alba Mill) lectin is an inhibitor of peroxidase from the same tissue. Proc. Rom Acad. 2011 Series B, vol 13, 1, 99-105

2010-Communications at National Congresses/ symposia not published or only available as an abstract

Budu C.E., Ashwini K, Clements D. Scott R

Antimicrobial Activities of Structurally diverse Host Protein Mimics. Poster at 50th ICAAC September 2010.

http://www.polymedix.com/pdf/ICAAC2010_Structurally-Diverse.pdf

2008-Articles in Scientific Journals with an International Referee System

Efendiev R, Budu C.E., Bertorello Am Pedemonte CH

G-protein-coupled receptor-mediated traffic of Na,K ATPase to the plasma membrane requires the binding of adaptor protein 1 to a Tyr-255-based sequence in the alpha subunit. J. Biol. Chem. 2008, 283, 17561-7

http://www.ncbi.nlm.nih.gov/pubmed/18420589

2008- Articles in Scientific Journals with a National Referee System

Ianculescu M, Budu C.E.

Detection of resistant individuals to SO2 pollution by using peroxidase activity regulated by a glycoprotein in Sessile Oak Seedlings (Quercus petrea (Matt) (Liebl). Proc. Rom Acad Series B, 2008 1-2, 101-107.

www.paulescu.ro/reviste/proceedings/pdf/2008/1…/art15Budu.pdf

2003- Articles in Scientific Journals with an International Referee System

Budu C.E., Luengpailin J, Reyes G, Doyle R.J. Cowan M.M.

Virulence factors of Porphyromanas Gingivalis are modified by Polyphenol oxidase and asparaginase. Oral Microbiol. Immunol. 2003; 18, 313-7.

http://www.ncbi.nlm.nih.gov/pubmed/12930524

Efendiev R, Budu C.E., Cinelli A.R., Bertorello A.M., Pedemonte C.H..

Intracelular Na+ regulates dopamine and angiotensin II receptors availability at the    plasma mambrane and their cellular respons in renal epithelia. J. Biol. Chem. 2003; 278, 28719-26.

http://www.ncbi.nlm.nih.gov/pubmed/12759348

2002– Articles in Scientific Journals with an International Referee System

Budu C.E., Efendiev R, Cinelli A.M., Bertorello A.M., Pedemonte C.H.

Hormonal-dependent recruitment of Na+K+ATPase to the plasmalemma is mediated by PKC beta and modulated by [Na]+i. Br. J. Phramacol. 2002; 137, 1380-6.

http://www.ncbi.nlm.nih.gov/pubmed/12466249

2002-Communications At international Congresses /Symposia not published or    available as an abstract.

Budu C.E.,

The Sugar Specificity and ribosome-inactivating protein activity of a bark lectin fron Fir (Abies alba Mill.) Abstract Book of INTERLEC 20, Meeting Ed. Bog- Hansen Thorkild 2002. p.48 TEXTOP Denmark.

Budu C.E.

Fir (Abies alba Mill.) Bark lectin AbA2 induces modifications on PKC beta and MAPK isozymes patterns followed by cytotoxicity on DLD1 colon cancer cell line. Abstract book of INTERLEC 20 Meeting, Ed. Bog-Hansen Thorkild, 2002 p.49 TEXTOP Denmark

2001– Articles in Scientific Journals with an International Referee System

Budu C.E., Balas N, Navrath H, Wegener JW, Shainberg A

Increased cardiac alpha -1 adrenoceptor density in rats following treatment with amiodarone. J. Basic Clin. Physiol. Pharmacol. 2001; 12, 33-47.

http://www.ncbi.nlm.nih.gov/pubmed/11414506

1994- Articles in Scientific Journals with a National Referee System

Shahar, A., C.E. Budu, A. Shainberg.

Cerebral neurons, skeletal myoblast and cardiac muscle cells cultured on maacroporous beads. Biotech. Bioeng., 43, 826-831, 1994.

1989– Communications At international Congresses /Symposia not published or    available as an abstract

Budu C.E., M. Ianculescu, I. Seceleanu.

Further research on peroxidase and two lectins from Fir (Abies alba Mill.). Kinetic Studies. Presented as poster at the 11th International lectin Conference, Tartu, USSR 1989.

1988– Articles in Scientific Journals with a National Referee System

Budu C.E., Z. Dobrescu, V. Antonescu.

Variation of certain biochemical markers due to the action of gamma radiation on sycamore maple (Acer pseudoplatanusL.) seeds. St. Cerc. Biochim. 31, 117-123, 1988.

Budu C.E. Isolation of two lectins from Fir (Abies Alba Mill.) bark tissue on                                  immobilized peroxidase   and some of their properties. Preliminary study. Rev. Roum. Biochim., 25, 1, 3-7 1988.

1987– Articles in Scientific Journals with a National Referee System

Budu C.E. Peroxidase in the phloem of forest trees and chemibioluminiscence.    Prospects in the physiological and ecological research. Rev. Padurilor, 102, 23-24. 1987

1979– Articles in Scientific Journals with a National Referee System

Mateeescu, M.A., C.E. Budu. The Influence of Rogor (Dimethoate) on the purified horseradish peroxidase. St. Cerc. Biochim. 22, 155-161, 1979.

Mateescu, M.A., H. D. Schell, C.E. Budu. Spectrophotometric method for the rapid determination of peroxidase activity. Possibuilities of simultaneous determination of p-diphenoloxidase (Laccase). Rev. Roum. Biochim. 16, 115-120, 1979.

Evelina Cohn Budu, PhD

Henrico, VA 23231

615-310-7362

ecohn2011@yahoo.com

www.linkedin.com/in/evelinacohn,

https://www.researchgate.net/profile/Evelina_Cohn_Budu

EXECUTIVE SUMMARY

Accomplished research scientist drawing on extensive experience in biochemistry, cancer biology, and microbiology. Demonstrated ability to manage multiple projects, utilizing a collaborative approach. Previous owner of successful skin care business, and leader of a non profit company, seeking markers for multiple sclerosis displaying proficiency in designing new procedures and innovative approaches. Adeptly generate ideas for use in grant writing and publications related to tumor and metastasis, biomarkers for brain injury and multiple sclerosis (MS).

KEY HIGHLIGHTS

  • Employ proven management skills by using innovative research techniques and finding new strategies to help people with neurodegenerative diseases. Submitted a provisional patent concerning novel glycoproteins in serum, possible biomarkers for neurodegenerative diseases.
  • Versatility in grant writing, from new ideas to research developments through a collaborative approach with Penn State University and Lampire Laboratories. Submitted a grant on point-of-care testing (POCT) for concussions and other traumatic brain injuries. Submitted two letters of intent regarding new glycoproteins in serum as biomarkers in neurodegenerative diseases, including MS and Parkinson’s.
  • Experience on line in advising companies and other peers with new technologies implemented in R&D departments through idea connection website.

PATENTS

Co-author of the Patent # 7,408,022 regarding apoptosis in cancer cell line. Patent issued on 2008

PROFESSIONAL EXPERIENCE

Executive Director | EVCO Scientific Inc., Philadelphia-PA

Oct 2013 – Present

  • Support operations in a volunteer capacity as a non- exempt, non-profit company by writing grants to fund the company and raising money for MS cause.
  • Involved in building and fostering relationships with Penn State University and Lampire Biological.

 

Innovator / Consultant| Ideaconnection.com, Victoria, Canada

Jul 2012 – Present

  • Perform online research addressing difficult problems to helping companies deliver hard to find technologies and techniques. Working in groups of 5 scientists from all over the world to generate innovations for R&D companies
  • Key Accomplishments:
  • Novel and Cost-Effective Synthesis Route for Dihydrochalcone
  • Alternative analysis for nitrosamines in agricultural organic products containing nitrogen.

Volunteer Researcher | University of Quebec at Montreal, Canada

Dec 2012; Mar 2013; Oct 2013

  • Conducted research in biochemistry, identifying novel glycoproteins in serum and potential personalized markers for MS and other neurodegenerative diseases.
  • Employed several new separation and detection procedures with success.

Scientist, Microbiology Area | PolyMedix, Radnor, PA

Aug 2009 – Feb 2012

  • Evaluated the Polymedix compounds for antimicrobial activities (MIC), killing kinetics, and resistance profiles against numerous Gram-negative and Gram-positive bacterial strains.
  • Completed a screen of over 200 compounds against large panel of bacterial strains under extremely tight timeframe for a government contract.
  • Assessed intracellular antimicrobial activity on macrophages of the most active compounds, including a clinical lead compound, toward MRSA.
  • Actively participated in routine laboratory meetings with the research head of the research department and research staff.
  • Communicated with supervisor, providing updates on experimental results, strategy, and directions

 

Self-Employed – Researcher / Consultant | TelBari Inc., Nashville, TN, and Philadelphia, PA

Apr 2006 – Dec 2011

  • Specialized in skin therapeutic formulations and research, designing therapeutic formulations for various skin diseases.
  • Managed activities from formulation to marketing and provided the final products to quality consumers. Identify target consumers, interested in natural products and/or having skin issues such as rosacea, eczema, psoriasis, very dry skin and burned skin.
  • Actively searched the market for new products and/or competitors. Wrote skin care articles. Considered expert writer by e-zine articles (ezinearticles.com) under aka Claudia Evelina Budu

Senior Scientist, Cancer Research | Celtek Bioscience, Nashville, TN

Apr 2003 – Apr 2006

  • Evaluated signal transduction pathways of different synthetic peptides in prostate cancer cell lines with emphasis to apoptotic cell signals. Patent accredited in 2008.
  • Made important contributions to new drug development in the area of targeted molecular therapies, typified by such compounds as Gleevec and Herceptin.
  • Organized and managed all laboratory research activities, such as employing methodologies, supervising lab assistant work, interpretation of the results and wrote research reports.

 

Post-Doctoral Scientist, Pharmacology | University of Houston, Houston, TX

Oct 2000 – Feb 2003

  • Assessed signal transduction pathways of hormone-induced augmentation of Na/K ATPase in opossum kidney and transfected cells.
  • Screened different receptors’ binding action (dopamine, serotonin agonist receptors, 8-OH-DPAT, and Angiotensin versus Na/K ATPase).
  • Examined raw data and performed statistical analysis.
  • Discovered that hormonal-induced Na/K ATPase is mediated by PKC beta and modulated by intracellular calcium.

Post-Doctoral Scientist-Microbiology | University of Louisville, Louisville, KY

Dec 1998 – Oct 2000

  • Evaluated adhesion-receptor interactions between anaerobe, aerobe bacteria, and host tissue after enzymatic treatment.
  • Discovered that some bacteria adhesins can chemically bind to Polyphenol oxidase (PPO) and that PPO inhibits protease trypsin-like activity of Porphyromonas gingivalis.
  • Mentoring and advising graduate students towards their dissertation and/or publications

 

Additional experience as Senior Scientist, Plant Genetics with Agriculture Research Institute in Israel and Romania.

EDUCATION

 

Ph.D. in Life Sciences | Bar Ilan University, Beit Dagan Israel

B.A. in Biochemistry | University of Bucharest, Bucharest, Romania

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,058 other subscribers
  • Recent Posts

    • Grok thinks like PhDs – Hybrid Model for Autonomous Update of Doctoral Dissertations with Original PhD Student Author editing and acceptance of Grok’s updated output. 3rd Joint article, a pilot study for Validation of an Autonomous Journal Articles Updating System (AJAUS) tested on Autonomous Update of Aviva Lev-Ari, PhD, RN Doctoral Thesis, UC, Berkeley, 1983. January 31, 2026
    • 2026 World Economic Forum, 1/19 – 1/23/2026, Davos, Switzerland, LPBI Group’s KOLs interpretation of AI in Health Videos January 24, 2026
    • Evolving LPBI Group’s Portfolio of Intellectual Properties (IP): From 2021 Vision to 2026 Reality January 12, 2026
    • Aviva Lev-Ari, PhD, RN – Biography ->> Grokepedia Entry January 11, 2026
    • List of Articles included in the Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Article SELECTION from Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com for Training Small Language Models (SLMs) in Domain-aware Content of Medical, Pharmaceutical, Life Sciences and Healthcare by 15 Subjects Matter January 10, 2026
    • Collection of Aviva Lev-Ari, PhD, RN Scientific Articles on PULSE on LinkedIn.com January 10, 2026
    • The youngest leader in AI in Health: Tanishq Mathew Abraham, Ph.D. (@iScienceLuvr) January 8, 2026
    • 2026 Grok Multimodal Causal Reasoning on Proprietary Cariovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage January 6, 2026
    • Workflow for Dynamic Linkage and Transition between two Authoring Systems: LPBI Group’s WordPress.com Multi-Authors Authoring System and Microsoft PowerPoint product for Slide show presentation – Part 10.1 in Composition of Methods January 6, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d